[1]
Alam, M.F.; Laskar, A.A.; Choudhary, H.H.; Younus, H. Human salivary aldehyde dehydrogenase: Purification, kinetic characterization and effect of ethanol, hydrogen peroxide and sodium dodecyl sulfate on the activity of the enzyme. Cell Biochem. Biophys., 2016, 74, 307-315.
[2]
Dyck, L.E. Polymorphism of a class 3 aldehyde dehydrogenase present in human saliva and in hair roots. Alcohol. Clin. Exp. Res., 1995, 19, 420-426.
[3]
Giebultowicz, J.; Wolinowska, R.; Sztybor, A.; Pietrzak, M.; Wroczynski, P.; Wierzchowski, J. Salivary aldehyde dehydrogenase: activity towards aromatic aldehydes and comparison with recombinant ALDH3A1. Molecules, 2009, 14, 2363-2372.
[4]
Wierzchowski, J.; Wroczynski, P.; Laszuk, K.; Interewicz, E. Fluorimetric detection of aldehyde dehydrogenase activity in human blood, saliva, and organ biopsies and kinetic differentiation between class I and class III isozymes. Anal. Biochem., 1997, 245, 69-78.
[5]
Giebultowicz, J.; Dziadek, M.; Wroczynski, P.; Woznicka, K.; Wojno, B.; Pietrzak, M.; Wierzchowski, J. Salivary aldehyde dehydrogenase - temporal and population variability, correlations with drinking and smoking habits and activity towards aldehydes contained in food. Acta Biochim. Pol., 2010, 57, 361-368.
[6]
Dolle, L.; Gao, B. Pharmacological chaperone therapies: Can aldehyde dehydrogenase activator make us healthier? J. Hepatol., 2015, 62, 1228-1230.
[7]
Glatt, H.; Rost, K.; Frank, H.; Seidel, A.; Kollock, R. Detoxification of promutagenic aldehydes derived from methylpyrenes by human aldehyde dehydrogenases ALDH2 and ALDH3A1. Arch. Biochem. Biophys., 2008, 477(2), 196-205.
[8]
Giebultowicz, J.; Wroczynski, P.; Samolczyk-Wanyura, D. Can lower aldehyde dehydrogenase activity in saliva be a risk factor for oral cavity cancer? Oral Dis., 2013, 19, 763-766.
[9]
Giebułtowicz, J.; Wroczyński, P.; Piekarczyk, J.; Wierzchowski, J. Fluorimetric detection of aldehyde dehydrogenase activity in human tissues in diagnostic of cancers of oral cavity. Acta Pol. Pharm., 2008, 65(1), 81-84.
[10]
Townsend, A.J.; Leone-Kabler, S.; Haynes, R.L.; Wu, Y.; Szweda, L.; Bunting, K.D. Selective protection by stably transfected human ALDH3A1 (but not human ALDH1A1) against toxicity of aliphatic aldehydes in V79 cells. Chem. Biol. Interact., 2001, 130-132, 261-273.
[11]
Bogucka, M.; Giebułtowicz, J.; Zawada, K.; Wroczyński, P.; Wierzchowski, J.; Pietrzak, M.; Piekarczyk, P.; Romanowska, K. The oxidation status of ALDH3A1 in human saliva and its correlation with antioxidant capacity measured by ORAC method. Acta Pol. Pharm., 2009, 66(5), 477-482.
[12]
Sladek, N.E. Human aldehyde dehydrogenases: Potential pathological, pharmacological, and toxicological impact. J. Biochem. Mol. Toxicol., 2003, 17, 7-23.
[13]
Sreerama, L.; Hedge, M.W.; Sladek, N.E. Identification of a class 3 aldehyde dehydrogenase in human saliva and increased levels of this enzyme, glutathione S-transferases, and DT-diaphorase in the saliva of subjects who continually ingest large quantities of coffee or broccoli. Clin. Cancer Res., 1995, 1, 1153-1163.
[14]
Laskar, A.A.; Alam, M.F.; Ahmad, M.; Younus, H. Kinetic and biophysical investigation of the inhibitory effect of caffeine on human salivary aldehyde dehydrogenase: Implications in oral health and chemotherapy. J. Mol. Struct., 2018, 1157, 61-68.
[15]
Wierzchowski, J.; Pietrzak, M.; Szelag, M.; Wroczynski, P. Salivary aldehyde dehydrogenase-reversible oxidation of the enzyme and its inhibition by caffeine, investigated using fluorimetric method. Arch. Oral Biol., 2008, 53, 423-428.
[16]
Alam, M.F.; Laskar, A.A.; Maryam, L.; Younus, H. Activation of human salivary aldehyde dehydrogenase by sulforaphane: Mechanism and significance. PLoS One, 2016, 11, e0168463.
[17]
Laskar, A.A.; Khan, M.A.; Askari, F.; Younus, H. Thymoquinone binds and activates human salivary aldehyde dehydrogenase: Potential therapy for the mitigation of aldehyde toxicity and maintenance of oral health. Int. J. Biol. Macromol., 2017, 103, 99-110.
[18]
Banh, A.; Xiao, N.; Cao, H.; Chen, C.H.; Kuo, P.; Krakow, T.; Bavan, B.; Khong, B.; Yao, M.; Ha, C.; Kaplan, M.J.; Sirjani, D.; Jensen, K.; Kong, C.S.; Mochly-Rosen, D.; Koong, A.C.; Le, Q.T. A novel aldehyde dehydrogenase-3 activator leads to adult salivary stem cell enrichment in vivo. Clin. Cancer Res., 2011, 17, 7265-7272.
[19]
Perez-Miller, S.; Younus, H.; Vanam, R.; Chen, C.H.; Mochly-Rosen, D.; Hurley, T.D. Alda-1 is an agonist and chemical chaperone for the common human aldehyde dehydrogenase 2 variant. Nat. Struct. Mol. Biol., 2010, 17, 159-164.
[20]
Stachowicz, A.; Olszanecki, R.; Suski, M.; Wisniewska, A.; Toton-Zuranska, J.; Madej, J.; Jawien, J.; Bialas, M.; Okon, K.; Gajda, M.; Glombik, K.; Basta-Kaim, A.; Korbut, R. Mitochondrial aldehyde dehydrogenase activation by Alda-1 inhibits atherosclerosis and attenuates hepatic steatosis in apolipoprotein E-knockout mice. J. Am. Heart Assoc., 2014, 3, e001329.
[21]
Xiao, N.; Cao, H.; Chen, C.H.; Kong, C.S.; Ali, R.; Chan, C.; Sirjani, D.; Graves, E.; Koong, A.; Giaccia, A.; Mochly-Rosen, D.; Le, Q.T. A novel aldehyde dehydrogenase-3 activator (Alda-89) protects submandibular gland function from irradiation without accelerating tumor growth. Clin. Cancer Res., 2013, 19, 4455-4464.
[22]
Zhong, W.; Zhang, W.; Li, Q.; Xie, G.; Sun, Q.; Sun, X.; Tan, X.; Jia, W.; Zhou, Z. Pharmacological activation of aldehyde dehydrogenase 2 by Alda-1 reverses alcohol-induced hepatic steatosis and cell death in mice. J. Hepatol., 2014, 62, 1375-1381.
[23]
Hahn, G. History, folk medicine, and legendary uses of garlic. In: Koch, H.P.; Lawson, L.D. (Eds.). Garlic: The science and therapeutic application of Allium sativum L and related species; ,Baltimore Williams and Wilkins,. , 1996. 2nd Edn,1-24.
[24]
Bayan, L.; Koulivand, P.H.; Gorji, A. Garlic: A review of potential therapeutic effects. Avicenna J. Phytomed., 2014, 4(1), 1-14.
[25]
Dewick, P.M. Medicinal natural products: A biosynthetic approach; John Wiley & Sons, 2009.
[26]
Kimura, S.; Tung, Y.C.; Pan, M.H.; Su, N.W.; Lai, Y.J.; Cheng, K.C. Black garlic: A critical review of its production, bioactivity, and application. J. Food Drug Anal., 2017, 25(1), 62-70.
[27]
Abdullah, T.H.; Kandil, O.; Elkadi, A.; Carter, J. Garlic revisited: therapeutic for the major diseases of our times? J. Natl. Med. Assoc., 1988, 80, 439-445.
[28]
Gebreyohannes, G.; Gebreyohannes, M. Medicinal values of garlic: A review. Int. J. Med. Med. Sci, 2013, 5(9), 401-408.
[29]
Kuete, V. Allium sativum.In: Kuete, V. (Eds.). Medicinal spices and vegetables from Africa; Academic Press, 2017, pp. 363-377.
[30]
Anwar, S.; Younus, H. Inhibitory effect of alliin from Allium sativum on the glycation of superoxide dismutase. Int. J. Biol. Macromol., 2017, 103, 182-193.
[31]
Asdaq, S.M.; Inamdar, M.N. Potential of garlic and its active constituent, S-allyl cysteine, as antihypertensive and cardioprotective in presence of captopril. Phytomedicine, 2010, 17(13), 1016-1026.
[32]
Chung, L.Y. The antioxidant properties of garlic compounds: Allylcysteine, alliin, allicin, and allyldisulfide. J. Med. Food, 2006, 9, 205-213.
[33]
Kourounakis, P.N.; Rekka, E.A. Effect on active oxygen species of alliin and Allium sativum (garlic) powder. Res. Commun. Chem. Pathol. Pharmacol., 1991, 74(2), 249-252.
[34]
Amani, H.; Ajami, M.; Maleki, S.N.; Pazoki-Toroudi, H.; Daglia, M.; Sokeng, A.J.; Di Lorenzo, A.; Nabavi, S.F.; Devi, K.P.
Nabavi, S.M. Targeting signal transducers and activators of transcription (STAT) in human cancer by dietary polyphenolic antioxidants. Biochimie, 2017, 142, 63-79.
[35]
Amani, H.; Habibey, R.; Hajmiresmail, S.J.; Latifi, S.; Pazoki-Toroudi, H.; Akhavan, O. Antioxidant nanomaterials in advanced diagnoses and treatments of ischemia reperfusion injuries. J. Mater. Chem. B, 2017, 5, 9452-9476.
[36]
Salman, H.; Bergman, M.; Bessler, H.; Punsky, I.; Djaldetti, M. Effect of a garlic derivative (alliin) on peripheral blood cell immune responses. Int. J. Immunopharmacol., 1999, 21(9), 589-597.
[37]
Sheela, C.G.; Augusti, K.T. Hypoglycemic effects of S-allyl cysteine sulphoxide isolated from garlic Allium sativum Linn. Indian J. Exp. Biol., 1992, 30, 523-526.
[38]
Wroczynski, P.; Wierzchowski, J.; Rakowska, A.; Chimkowska, M.; Targonski, J. Aldehyde dehydrogenase in human saliva-evaluation of its oxidation status. Acta Pol. Pharm., 2004, 61, 62-64.
[39]
Smith, P.K.; Krohn, R.I.; Hermanson, G.T.; Mallia, A.k.; Gartner, F.H.; Provenzano, M.D.; Fujimoto, E.K.; Goeke, N.M.; Olson, B.J.; Klenk, D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem., 1985, 150, 76-85.
[40]
Laskar, A.A.; Alam, M.F.; Younus, H. In vitro activity and stability of pure human salivary aldehyde dehydrogenase. Int. J. Biol. Macromol., 2017, 96, 798-806.
[41]
Michaelis, L.; Menten, M.L.; Johnson, K.A.; Goody, R.S. The original Michaelis constant: Translation of the 1913 Michaelis-Menten paper. Biochemistry, 2011, 50, 8264-8269.
[42]
Lineweaver, H.; Burk, D. The determination of enzyme dissociation constants. J. Am. Chem. Soc., 1934, 56, 658-666.
[43]
Perez-Iratxeta, C.; Andrade-Navarro, M.A. K2D2: Estimation of protein secondary structure from circular dichroism spectra. BMC Struct. Biol., 2008, 8, 25.
[44]
Kuntz, I.D.; Chen, K.; Sharp, K.A.; Kollman, P.A. The maximal affinity of ligands. Proc. Natl. Acad. Sci. USA, 1999, 96(18), 9997-10002.
[45]
Abad-Zapatero, C. Ligand efficiency indices for effective drug discovery. Expert Opin. Drug Discov., 2007, 2(4), 469-488.
[46]
Hopkins, A.L.; Groom, C.R.; Alex, A. Ligand efficiency: A useful metric for lead selection. Drug Discov. Today, 2004, 9(10), 430-431.
[47]
Abad-Zapatero, C.; Metz, J.T. Ligand efficiency indices as guideposts for drug discovery. Drug Discov. Today, 2005, 10(7), 464-469.
[48]
Koppaka, V.; Thompson, D.C.; Chen, Y.; Ellermann, M.; Nicolaou, K.C.; Juvonen, R.O.; Petersen, D.; Deitrich, R.A.; Hurley, T.D.; Vasiliou, V. Aldehyde dehydrogenase inhibitors: A comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharmacol. Rev., 2012, 64, 520-539.
[49]
Hopkins, A.L.; Keserü, G.M.; Leeson, P.D.; Rees, D.C.; Reynolds, C.H. The role of ligand efficiency metrics in drug discovery. Nat. Rev. Drug Discov., 2014, 13(2), 105-121.
[50]
Schultes, S.; de Graaf, C.; Haaksma, E.E.; de Esch, I.J.; Leurs, R.; Krämer, O. Ligand efficiency as a guide in fragment hit selection and optimization. Drug Discov. Today. Technol., 2010, 7(3), e147-e202.
22
2